Metraipolis › archive › dc_e5eb7d972098

Real-World Effectiveness of Risankizumab in Crohn's Disease: Outcome Data for an IL-23 Inhibitor from the Middle East — Europe PMC PMID:41346973

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41346973
DOI
10.1093/crocol/otaf062
License (as archived)
solo-consultazione
Archived
2026-11-09T14:57:40.668Z
SHA-256 of the archived text
0ca6d7d6385b740143ee8b6895a238b74690bc50c5b2ec6f4da8cea299160b01
Stable URL of this page
https://metraipolis.com/documento/dc_e5eb7d972098

How to cite

Real-World Effectiveness of Risankizumab in Crohn's Disease: Outcome Data for an IL-23 Inhibitor from the Middle East — Europe PMC PMID:41346973 — Europe PMC (en), https://europepmc.org/article/MED/41346973 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e5eb7d972098 (Metraipolis archive dc_e5eb7d972098, sha256 0ca6d7d6385b740143ee8b6895a238b74690bc50c5b2ec6f4da8cea299160b01)
BibTeX
@misc{dce5eb7d972098,
  title = {Real-World Effectiveness of Risankizumab in Crohn's Disease: Outcome Data for an IL-23 Inhibitor from the Middle East — Europe PMC PMID:41346973},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41346973},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e5eb7d972098; sha256 0ca6d7d6385b740143ee8b6895a238b74690bc50c5b2ec6f4da8cea299160b01},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41346973. Agents can read the archived copy with the MCP tool read_document.